Paul Goldberg is the editor and publisher of The Cancer Letter, a weekly publication focused on drug development and the politics of cancer. After joining that publication in 1986, he uncovered a key element of a scandal at a genomics research group at Duke University. This led to retraction of papers in the world’s premier medical journals and appointment of a committee of the Institute of Medicine.

Goldberg also broke the story that led to the ImClone scandal and the key stories in the controversy over erythropoiesis-stimulating agents. His reporting on the pharmaceutical and biotechnology industry has triggered numerous investigations by Congressional committees and law enforcement agencies and has been recognized by the Washington DC Professional Chapter of the Society of Professional Journalists, the Gerald Loeb Awards, and the Newsletter and Electronic Publishers Foundation.

His articles have appeared in The New York Times, The Wall Street Journal, The Washington Post and The Washington Monthly, and he has been featured on 60 Minutes, 20/20, CNN and NPR.

His books include "How We Do Harm: A Doctor Break Ranks About Being Sick in America," with Otis Brawley, (St. Martin’s Press, 2012). He co-wrote a history of the Helsinki Watch group in the former USSR, called "The Final Act" (William Morrow, 1988), and co-authored, with Ludmilla Alexeyeva, "The Thaw Generation: Coming of Age in the Post-Stalin Era" (Little, Brown, 1990; and in paperback, University of Pittsburgh Press). Goldberg also translated from the Russian, "To Live Like Everyone," the memoirs of the late dissident Anatoly Marchenko (Henry Holt, 1989). He is a graduate of Duke University with a B.A. in economics (1981).

• The mission of The Cancer Letter is to report on current and controversial topics in oncology.
• Company policy doesn't allow the publisher or staff to hold individual stock positions in healthcare, pharmaceutical, or biotechnology companies.